Eric Castaldi joins Hybrigenics

Published: 27-Oct-2008

Eric Castaldi becomes non-director of Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialised in protein interactions.


Eric Castaldi becomes non-director of Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialised in protein interactions.

Castaldi brings 20 years of financial experience, especially from the medical and biotechnology fields. He is chief financial officer and a member of the executive committee of NicOx SA, an emerging pharmaceutical company listed on Eurolist in Paris, and which is specialised in the research and development of nitric oxide-donating drugs.

"I am delighted to welcome Eric to our board," said Daan Ellens, chairman of the Board of Hybrigenics. "His solid financing track record in the biotechnology sector and his in-depth experience of the challenges faced by listed companies will be very helpful to further structure our company."

You may also like